Skip to main content
. Author manuscript; available in PMC: 2013 Apr 11.
Published in final edited form as: Pigment Cell Melanoma Res. 2010 Dec;23(6):820–827. doi: 10.1111/j.1755-148X.2010.00763.x

Figure 4. PLX4032 Initiates Potent Tumor Regression in V600E-positive Xenografts.

Figure 4

A,B) Xenograft tumors established from either B-Raf wild-type (A) or mutant (B) cell lines were administered 100 mg/ml PLX4032 BID and tumor volume was recorded every 72 hours for 15 days. C) 1205Lu tumors from control and treated mice were harvested, paraffin-embedded, and stained with pERK to measure target efficacy. Photos are depicted at 40x magnification. D) 1205Lu tumors control and treated mice were harvested, paraffin-embedded, and stained with Ki67 to indicate relative proliferation within respective tumors. E) Pharmocokinetic analysis of plasma drug levels from xenografts on the first and last day of treatment at 2- and 6-hours post treatment.